APOB and fatty liver disease: Studies have shown that some drugs activate PPARα, leading to lipolysis and fatty acid oxidation in adipose tissue and increasing the circulating fatty acid level and their transfer to the liver, resulting in disorders of PPARγ and ApoB, further insulin resistance and hepatic steatosis (Renu et al., 2019) (Ben-Yakov et al., 2019) (for the Drug-Induced Liver Injury Network et al., 2019).